Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries.
• While targeted therapies like BTK and BCL-2 inhibitors have improved outcomes, long-term management of double-refractory CLL remains a challenge.
• Therapy resistance in CLL can stem from BTK mutations, BCL-2 pathway alterations, and tumor microenvironment adaptations.

Purpose of the Study:

• To provide an in-depth overview of novel therapeutic approaches under investigation for CLL.
• To highlight treatments targeting resistance mechanisms in double-refractory CLL.
• To discuss ongoing clinical trials and the potential of new agents.

Main Methods:

• Review of current scientific literature and ongoing clinical trials.
• Focus on emerging treatment modalities including cellular therapies and novel small molecule inhibitors.
• Discussion of therapeutic targets and resistance mechanisms in CLL.

Main Results:

• Several novel treatment strategies show promise for CLL management.
• Advanced cellular therapies (CAR T-cell therapy) and T-cell engagers are being explored.
• Next-generation small molecule inhibitors (e.g., BTK degraders, PI3K inhibitors, MALT1 inhibitors) offer new avenues.

Conclusions:

• New therapeutic options are crucial for overcoming resistance in CLL, particularly in double-refractory disease.
• Investigational agents targeting angiogenesis and DNA damage repair are also under study.
• These novel treatments hold potential to address unmet needs in challenging CLL cases.